Related Experiment Videos
Acute treatments: future developments
1Lilly Research Laboratories, Eli Lilly & Co. and Indiana University School of Medicine, Indianapolis, Indiana 46285, USA. ramadan@lilly.com
Current Medical Research and Opinion
|December 5, 2002
Summary
Future migraine therapies focus on CGRP antagonists, nitric oxide synthase inhibitors, and glutamate receptor antagonists. These novel treatments aim for high efficacy with improved safety and tolerability, with trials underway.
Area of Science:
- Neurology
- Pharmacology
- Drug Development
Background:
- Previous anti-migraine drug development faced challenges and dead ends.
- Current acute treatments may have limitations in efficacy or tolerability.
- Emerging research targets novel pathways for migraine management.
Purpose of the Study:
- To review promising future therapeutic targets for acute migraine.
- To discuss the potential of novel drug classes in migraine treatment.
- To highlight the ongoing research and development in anti-migraine therapies.
Main Methods:
- Review of current literature and clinical trial data.
- Discussion of emerging drug targets including CGRP antagonists, NOS inhibitors, and glutamate receptor antagonists.
- Analysis of the potential efficacy and safety profiles of novel agents.
Main Results:
- Growing interest and support for CGRP antagonists, nitric oxide synthase inhibitors, and ionotropic glutamate receptor antagonists.
- Several novel targets are in early efficacy or first human dose trials.
- Anticipation for large-scale efficacy and safety trials of these future therapies.
Conclusions:
- Novel drug targets show promise for effective and well-tolerated migraine treatment.
- The development pipeline for acute migraine therapies is advancing with promising candidates.
- Further clinical trials are crucial to validate the efficacy and safety of these future migraine treatments.